title: The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization.
abstract: OBJECTIVE
  To investigate whether pituitary desensitization with the gonadotropin-releasing hormone agonist (GnRH-a), buserelin acetate, before the administration of human menopausal gonadotropin (hMG) for ovarian stimulation in in vitro fertilization (IVF) is superior to the simultaneous administration of both hormones at the beginning of the treatment cycle.
  
  
  METHODS
  Prospective randomized study.
  
  
  METHODS
  Ninety-one patients having their first attempt at IVF.
  
  
  METHODS
  Patients in group 1 (long protocol) were administered subcutaneous (SC) buserelin acetate 200 micrograms/d from day 1 of the menstrual cycle, and hMG was started only after pituitary desensitization had been achieved at least 14 days later. Patients in group 2 (short protocol) were administered SC buserelin acetate 200 micrograms/d from day 2 and the same dose of hMG used in the long protocol from day 3 of the menstrual cycle.
  
  
  RESULTS
  The median total amount of hMG required in both groups was comparable. There were significantly more follicles (P = 0.0001), oocytes (P = 0.0008), fertilized oocytes (P = 0.0001), and cleaved embryos (P = 0.0001), and a higher fertilization rate (P = 0.0047) in patients in group 1. The pregnancy rates per initiated cycle and per embryo transfer were 19.57% and 25.71% in group 1 compared with 8.89% and 16.67% in group 2.
  
  
  CONCLUSIONS
  The long protocol is superior in terms of significantly greater follicular recruitment, oocyte recovery and fertilization rates, and significantly greater number of embryos available for transfer. In general, it is the preferred method when GnRH-a are used for ovarian stimulation in IVF.
authors.affiliation: Hallam Medical Centre, London, United Kingdom.
authors.forename: S L
authors.initials: SL
authors.lastname: Tan
authors.forename: C
authors.initials: C
authors.lastname: Kingsland
authors.forename: S
authors.initials: S
authors.lastname: Campbell
authors.forename: C
authors.initials: C
authors.lastname: Mills
authors.forename: J
authors.initials: J
authors.lastname: Bradfield
authors.forename: N
authors.initials: N
authors.lastname: Alexander
authors.forename: J
authors.initials: J
authors.lastname: Yovich
authors.forename: H S
authors.initials: HS
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female; D007248:Infertility, Male; D008297:Male; D011336:Probability; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
chemical_list: D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C019176:Tryptal